araag2/HINT huggingface dataset:
Clinical trial NCT01008423 (phase 3, status: completed)
Conditions: proctitis, proctosigmoiditis
ICD codes: K62.7, K51.20, K51.213, K51.214, K51.211, K51.212, K51.218
Drugs: budesonide, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Voluntarily sign written informed consent.

          -  Male or non-pregnant and non-lactating females.

          -  Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate UP or UPS,
             with disease extending at least 5 centimeters (cm) but no further than 40 cm from the
             anal verge.

          -  Must possess a baseline MMDAI score between 5 and 10.

        Exclusion Criteria:

          -  History or current diagnosis of Crohn's disease and indeterminate colitis.

          -  Prior gastrointestinal surgery except appendectomy and hernia.

          -  Concomitant active gastrointestinal disease or distortion of intestinal anatomy.

          -  History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic
             or known gallbladder disease.

          -  Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.

          -  Uncontrolled abnormal thyroid function.

          -  Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.

          -  Hemoglobin levels less than (<) 7.5 grams /deciliter (g/dL).

          -  History of sclerosing cholangitis, cirrhosis, or hepatic impairment.

          -  Renal disease manifested by greater than (>) 2.0 milligrams/deciliter (mg/dL) serum
             creatinine.

          -  History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or
             ocular varicella zoster, malignant disease, and HIV or hepatitis B or C.

          -  Adrenal insufficiency.

          -  Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or
             abscess.

          -  History of uncontrolled psychiatric disorders or seizure disorders.

          -  History of asthma requiring ongoing use of inhaled steroids.

          -  Recent history of drug or alcohol abuse.

          -  Positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and
             parasites.

          -  Vaccination within 28 days prior to randomization.

          -  Allergies to budesonide or to any other items used in its preparation.

          -  Participation in another clinical trial in the past 30 days.

          -  Pregnant or at risk of pregnancy.

          -  Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during
             participation in the study, including laxatives and anti-diarrhea medications;
             however, oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements are
             allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant
             medicines) are also prohibited.
Clinical trial NCT00330369 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: darusentan, darusentan placebo
SMILES: COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1, COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who are competent to provide written consent

          -  Aged 35 to 80 years

          -  Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood
             pressure ≥130 mmHg

          -  All other subjects must have a mean systolic blood pressure ≥140 mmHg

          -  Receiving and adhering to full doses of appropriate guideline-recommended
             antihypertensive drugs from three different classes of antihypertensive agents,
             including a diuretic

          -  Female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2
             years; surgically sterile)

        Exclusion Criteria:

          -  Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110
             mmHg

          -  Serum ALT or AST >2 x the upper limit of the normal range (ULN)

          -  Subjects who have experienced myocardial infarction, unstable angina pectoris, or a
             cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or
             third degree atrioventricular block, atrial fibrillation or recurrent atrial
             tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia

          -  Implanted pacemakers or implanted cardioverter defibrillator (ICD)

          -  Symptomatic congestive heart failure requiring treatment

          -  Hemodynamically significant valvular heart disease

          -  Type I diabetes mellitus

          -  Hemodialysis or peritoneal dialysis; or history of renal transplant

          -  Diagnosis or recurrence of malignancy within the past 3 years

          -  Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation
             greater than or equal to 90%

          -  Subjects who perform alternating shift or night work

          -  Subjects who have participated in a clinical study involving another investigational
             drug or device within 4 weeks prior to Screening
Clinical trial NCT00634400 (phase 3, status: completed)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: candesartan, placebo
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 or above

          -  Congestive Heart Failure with symptoms for more than 4 weeks before starting study

          -  Provision of informed consent

        Exclusion Criteria:

          -  Current low blood pressure with symptoms

          -  Liver disease considered significant by the study doctor

          -  Pregnant or lactating females
Clinical trial NCT00661661 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who have completed their participation in a randomized "qualifying" study of
             CP-690,550 for the treatment of rheumatoid arthritis

        Exclusion Criteria:

          -  Serious medical conditions that would make treatment with CP-690,550 potentially
             unsafe
Clinical trial NCT01049334 (phase 3, status: completed)
Conditions: pharyngitis
ICD codes: A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8
Drugs: placebo, flurbiprofen
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. The patient has a complaint of sore throat.

          2. If the patient is a female of childbearing potential, she has been using effective
             contraception since the last date of menses and is not breast-feeding or lactating.

          3. If the patient is a female of childbearing potential, the patient must have a negative
             urine pregnancy.

          4. The patient has provided written informed consent prior to any study-related
             procedures.

        Exclusion Criteria:

          1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days,
             is currently experiencing clinically significant upper gastrointestinal complaints, or
             is currently taking medication regularly (≥ three times in the previous week).

          2. The patient has a history of any hepatic disease or renal dysfunction.

          3. The patient has a history of chronic analgesic use (≥ three times per week over the
             prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study
             per investigator's clinical decision.)
Clinical trial NCT00003686 (phase 3, status: terminated)
Conditions: oral complications, quality of life
ICD codes: E10.638, E11.638, E13.638, E08.638, E09.638
Drugs: pilocarpine hydrochloride, placebo
SMILES: CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated due to poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Complaint of dry mouth with ALL the following characteristics: At
        least 1 week in duration Attributed by the treating physician to an opioid Severity rating
        at least 20 mm on a 100 mm visual analog scale Must be receiving routine (i.e., not just as
        needed) dosing with one of the following opioids: morphine, hydromorphone, transdermal
        fentanyl, methadone, or oxycodone Intent to continue opioid therapy at the same or higher
        dose over the first 2 weeks that the patient is receiving protocol treatment

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy: At
        least 6 weeks Hematopoietic: Not specified Hepatic: Not specified Renal: Calcium less than
        29.9 mg/dL Cardiovascular: No symptomatic congestive heart failure or hypotension (systolic
        blood pressure less than 100 mm Hg) Pulmonary: No obstructive pulmonary disease (asthma,
        chronic bronchitis, or chronic obstructive pulmonary disease) Other: No known sensitivity
        to pilocarpine No active oral candidiasis No Sjogren's syndrome No acute iritis or
        narrow-angle glaucoma Not pregnant or nursing Effective contraception required of all
        fertile patients Must be fluent and possess sufficient cognitive ability to complete
        quality of life questionnaires in either English or French without assistance from a
        caregiver

        PRIOR CONCURRENT THERAPY: See Disease Characteristics Biologic therapy: Not specified
        Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior
        radiotherapy to a field encompassing the parotid glands At least 1 week since prior
        radiotherapy to the chief site of pain No concurrent radiotherapy to chief site of pain for
        2 weeks following randomization Surgery: Not specified Other: No concurrent tricyclic
        antidepressants (amitriptyline, nortriptyline, desipramine, or imipramine)
Clinical trial NCT00532935 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate (+) metformin hydrochloride, comparator: pioglitazone
SMILES: CN(C)C(=N)NC(N)=N, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        General Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus

          -  Patient is inadequately controlled and not on treatment with insulin or oral
             antihyperglycemic therapy

        General Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 12
             weeks

          -  Patient was on >4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin)
             over the prior 3 years
Clinical trial NCT00440271 (phase 3, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: tipranavir, ritonavir, optimized background regimen (obr)
SMILES: [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        Main inclusion criteria for the study are:

          1. HIV-1 infected adults, men and women at least 18 years of age.

          2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse
             transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) treatment-experienced
             (min of 3-months duration for each class) with resistance to more than one PI (on
             screening resistance testing). NNRTI-naïve patients who have genotypically documented
             NNRTI-resistance mutations on past or screening resistance testing would be eligible.

          3. CD4+ T lymphocyte count >=50 cells/mm3.

          4. HIV-1 viral load >=1,000 copies/mL at screening.

          5. The antiretroviral (ARV) study treatment regimen must consist of TPV/r in combo with
             an optimized background regimen (OBR) of 2-4 agents: N(t)RTIs (NRTI or NtRTI),
             enfuvirtide (ENF), and/or, where available, a trial approved expanded access program
             (EAP) investigational agent.

          6. Acceptable screening laboratory values that indicate adequate baseline organ function.

          7. Acceptable medical history with a chest X-ray without evidence of active disease and
             an electrocardiogram (ECG) without clinically important abnormalities within one year
             of the study.

          8. A reliable method of barrier contraception will be used by all female patients who are
             of childbearing potential.

        Exclusion Criteria:

        Main exclusion criteria for the study are:

          1. Known hypersensitivity to the tipranavir (TPV) or ritonavir (RTV).

          2. ARV medication naïve.

          3. Genotypic resistance to TPV (defined as a TPV mutation score >7).

          4. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for
             at least 7 consecutive days within the month prior to screening.

          5. Prior tipranavir use.

          6. Inability to adhere to the requirements of the protocol.

          7. Patients with prior history of hemorrhagic stroke or intracranial aneurysm.

          8. Patients with a history of ischemic stroke, neurosurgery or skull trauma within 4
             weeks prior to screening.

          9. History of Progressive Multifocal Leukoencephalopathy, Visceral Kaposi's Sarcoma,
             and/or any malignancy.

         10. Any acquired immunodeficiency syndrome (AIDS) defining illness that is unresolved,
             symptomatic or not stable on treatment for at least 12 weeks at screening visit.
Clinical trial NCT00612170 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: [s,s]-reboxetine, placebo, [s,s]-reboxetine, [s,s]-reboxetine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female of any race, at least 18 years of age

          -  Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for
             at least 3 months, and pain in at least 11 of 18 specific tender point sites)

        Exclusion Criteria:

          -  Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic
             Neuralgia) that may confound assessment or self evaluation of the pain associated with
             fibromyalgia

          -  Patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other
             than fibromyalgia), active infection, or untreated endocrine disorder

          -  A current or recent diagnosis (last 6 months) or episode of major depressive disorder,
             dysthymia and/or uncontrolled depression

          -  History of mania, hypomania, other psychotic disorder, or current mood disorder with
             psychotic features
Clinical trial NCT00189553 (phase 3, status: completed)
Conditions: ovarian cancer, fallopian tube cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02
Drugs: pegylated liposomal doxorubicin, carboplatin, paclitaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged > 18

          -  Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
             extra-ovarian papillary serous tumors

          -  Measurable disease (Response Evaluation Criteria in Solid Tumor [RECIST] criteria) or
             cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG]
             criteria) or with histologically proven diagnosis of relapse

          -  Disease in progression > 6 months after a first or second platinum-based line.
             Patients should have previously received a taxane derivative.

          -  ECOG performance status < 2

          -  Life expectancy of at least 12 weeks

          -  Adequate bone marrow, renal, and hepatic function

        Exclusion Criteria:

          -  Ovarian tumors of low malignant potential

          -  Non-epithelial ovarian or mixed epithelial/non-epithelial tumors

          -  Previous radiotherapy

          -  Prior diagnosis of malignancy

          -  Bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases

          -  Pre-existing motor or sensory neurologic pathology or symptoms National Cancer
             Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 1

          -  History of congestive heart failure (New York Heart Association [NYHA] classification
             > 2), history of myocardial infarction within the last 6 months, or history of atrial
             or ventricular arrhythmias

          -  Severe active infection

          -  Severe hypersensitivity to products containing Cremophor EL and/or to compounds
             chemically related to paclitaxel, carboplatin or Caelyx

          -  Fertile women not using adequate contraceptive methods

          -  Pregnant or breast feeding women
Clinical trial NCT01689129 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin glargine new formulation (hoe901), insulin glargine (hoe901) (lantus)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients with type 1 diabetes mellitus

        Exclusion criteria:

          -  Age < 18 years at screening visit;

          -  HbA1c < 7.0 % or > 10.0 % (national glycohemoglobin standardization program [NGSP]
             value) at screening visit;

          -  Patients less than 1 year before screening visit on any basal plus mealtime insulin;

          -  Patients not on stable insulin dose (±20% total basal insulin dose) in the last 30
             days prior to screening visit;

          -  Patients using pre-mix insulins, human regular insulin as mealtime insulin and/or any
             glucose-lowering drugs other than basal insulin and mealtime rapid-insulin analogue in
             the last 3 months before screening visit;

          -  Use of an insulin pump in the last 6 months before screening visit and/or plan to
             switch to insulin pump in next 12 months;

          -  Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic
             ketoacidosis in the last 6 months before screening visit;

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eq, laser, surgical
             treatment or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00698932 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with Type 2 diabetes

          -  Patients should be drug naïve ie, not received medical treatment for diabetes,

          -  HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)

        Exclusion Criteria:

          -  Insulin therapy within one year of enrolment (with the exception of insulin therapy
             during a hospitalization or use in gestational diabetes),

          -  Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma
Clinical trial NCT00230763 (phase 3, status: completed)
Conditions: glaucoma, primary open angle (poag), ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: latanoprost 0.005% / timolol 0.5% fixed combination
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients,

          -  Aged > than equal to 18 years,

          -  Patient presenting with an OHT or OAG with an IOP � 21 mmHg,

          -  Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a
             change of the ophthalmic medication due to insufficient response to treatment,

        Exclusion Criteria:

          -  Patient currently treated by or having received within the last month any ophthalmic
             hypotensive agent other than a beta-blocker,

          -  Patient presenting any contraindication to latanoprost or timolol,

          -  Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia
             (pulse rate < 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud
             disease or any other condition that would preclude the patient from taking the
             prescribed medication,

          -  Patient with known intolerance to benzalkonium chloride or any excipient contained in
             the trial treatment,
Clinical trial NCT00701090 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus, non insulin dependent, diabetes mellitus, non-insulin-dependent
ICD codes: F60.7, R39.192, E24.0, D81.818, D81.819, Z63.6, G40.42, E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: sitagliptin, comparator: glimepiride, open-label metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Diagnosed with type 2 diabetes

          -  On a stable dose of metformin of at least 1500 mg per day

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  Pregnant

          -  HIV positive

          -  On a weight loss program or medication

          -  Has a history of blood disorder, certain cancers, heart, liver or kidney disease